MUTYH-associated polyposis (MAP) is an inherited disorder characterized by an increased tendency to develop colorectal polyps and colorectal cancer. It results from disease-causing variants in both copies of the MUTYH gene, which participates in repairing oxidative damage to DNA. Most affected individuals develop multiple adenomatous polyps during adulthood, but the number varies widely, and colorectal cancer can occur without extensive polyposis. MAP follows an autosomal recessive inheritance pattern, distinguishing it from several other inherited colorectal cancer syndromes.
Genetic basis and disease mechanism
MUTYH encodes a DNA glycosylase, an enzyme involved in base excision repair. Its principal function is to remove adenine that has been incorrectly paired with oxidized guanine, particularly 8-oxoguanine. This process helps prevent oxidative damage from becoming a permanent change in the DNA sequence.
When both copies of MUTYH have pathogenic variants, this repair function is impaired. Cells accumulate characteristic mutations, including changes conventionally described as G:C-to-T:A transversions. Mutations affecting genes that control intestinal cell growth can contribute to polyp formation and subsequent malignant transformation.
The two pathogenic variants may be identical, termed homozygosity, or different, termed compound heterozygosity. In the latter situation, the variants must affect opposite copies of the gene—one inherited from each parent—to establish the usual genetic basis of MAP. Not every MUTYH variant disrupts function; a variant of uncertain significance does not by itself establish the disorder.
Inheritance and occurrence
MAP has autosomal recessive inheritance. An affected person usually inherits one pathogenic variant from each parent. Parents who each carry one pathogenic variant generally do not have MAP.
When both parents are carriers, each pregnancy has a:
- 25% probability of a child inheriting two pathogenic variants and having MAP;
- 50% probability of a child inheriting one pathogenic variant and being a carrier;
- 25% probability of a child inheriting neither familial variant.
These probabilities apply independently to each pregnancy. Because carriers may have no obvious manifestations, an affected person may lack a family history of extensive polyposis or early colorectal cancer. Several affected siblings within one generation can be a clue to recessive inheritance.
MAP occurs in multiple populations. The variants p.Tyr179Cys and p.Gly396Asp are particularly well characterized in people of European ancestry, but many other disease-causing variants exist. Testing limited to a small set of common variants does not detect every affected individual.
Clinical features
Colorectal manifestations
The typical finding is multiple colorectal adenomas, often numbering from tens to a few hundred over time. Adenomas are gland-forming polyps with the potential to progress to cancer, although an individual adenoma does not inevitably become malignant. Some affected individuals also have serrated or hyperplastic polyps.
Presentation is variable. Some people have relatively few polyps, whereas others develop a much heavier polyp burden. Colorectal cancer may be the first recognized manifestation, including in individuals without numerous previously documented polyps.
Possible manifestations include rectal bleeding, altered bowel habits, abdominal pain, or iron-deficiency anemia caused by gastrointestinal blood loss. Polyps and early cancers can also be asymptomatic.
Manifestations outside the colorectum
Adenomas can occur in the duodenum, and duodenal cancer risk is increased. Gastric polyps and other upper gastrointestinal findings have also been reported.
Studies have described cancers at additional sites in people with MAP, but the strength and precision of risk estimates vary. The most firmly established tumor risks concern the colorectum and duodenum. MAP does not consistently reproduce the full range of extracolonic features seen in classic familial adenomatous polyposis.
Diagnosis
The molecular diagnosis is established by identifying pathogenic or likely pathogenic germline variants in both copies of MUTYH. Germline testing typically uses DNA from blood or another non-tumor sample.
Testing may be performed as part of a multigene panel for hereditary colorectal cancer or polyposis because the clinical appearance overlaps with other conditions. Methods may include sequence analysis and testing for larger gene deletions or duplications. Interpretation can require determining whether two detected variants lie on opposite gene copies.
Colonoscopy establishes the distribution and burden of colorectal polyps, while examination of removed tissue determines their histological type. Upper gastrointestinal endoscopy can identify duodenal and other upper gastrointestinal lesions.
Tumor sequencing may reveal mutational patterns associated with MUTYH deficiency, notably signatures designated SBS18 and SBS36. Such findings can support further investigation but do not independently replace germline testing.
Differential diagnosis
Important alternatives include:
- Familial adenomatous polyposis, caused by pathogenic variants in APC. Its attenuated form can closely resemble MAP.
- Lynch syndrome, caused by defects affecting DNA mismatch repair and generally not characterized by extensive adenomatous polyposis.
- Other inherited polyposis syndromes, including those involving NTHL1, POLE, or POLD1.
- Multiple sporadic adenomas without an identified inherited cause.
Polyp count and family history alone do not reliably distinguish these conditions.
Clinical management
Clinical management centers on detecting and removing precancerous lesions and treating established cancer. Published specialist protocols use repeated colonoscopy with polyp removal, together with upper gastrointestinal surveillance. The timing and extent of surveillance vary with age, previous findings, polyp burden, and the guideline being applied.
Surgery is used when colorectal cancer is present or when the number, size, or pathological features of polyps make endoscopic control inadequate. Surgical approaches differ according to the distribution of disease and involvement of the rectum. Remaining colorectal tissue continues to be relevant to surveillance after surgery.
Genetic counseling addresses inheritance, interpretation of test results, and testing of relatives. Identifying the familial variants allows relatives to be distinguished as affected individuals, single-variant carriers, or noncarriers.
Single-variant carriers and evidence limitations
A person with only one pathogenic MUTYH variant is a monoallelic carrier and does not, on that finding alone, have MAP. Cancer-risk estimates for carriers have varied across studies and depend partly on family history and how study participants were selected. The substantial colorectal cancer predisposition associated with biallelic MAP should not be attributed automatically to single-variant carriers.
Risk estimates for MAP also have limitations. Many studies involve families identified through cancer clinics, which can overrepresent severe disease. Surveillance and polyp removal alter the natural course of the disorder, so risks observed in untreated historical groups are not directly equivalent to outcomes under contemporary clinical care.